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Metastasis is a multistep process including dissociation of cancer cells from primary sites, survival in the vascular system, and
proliferation in distant target organs. As a barrier to metastasis, cells normally undergo an apoptotic process known as “anoikis,”
a form of cell death due to loss of contact with the extracellular matrix or neighboring cells. Cancer cells acquire anoikis resistance
to survive after detachment from the primary sites and travel through the circulatory and lymphatic systems to disseminate
throughout the body. Because recent technological advances enable us to detect rare circulating tumor cells, which are anoikis
resistant,currently,anoikisresistancebecomesahottopicincancerresearch.Detailedmolecularandfunctionalanalysesofanoikis
resistant cells may provide insight into the biology of cancer metastasis and identify novel therapeutic targets for prevention
of cancer dissemination. This paper comprehensively describes recent investigations of the molecular and cellular mechanisms
underlying anoikis and anoikis resistance in relation to intrinsic and extrinsic death signaling, epithelial-mesenchymal transition,
growth factor receptors, energy metabolism, reactive oxygen species, membrane microdomains, and lipid rafts.
1.Introduction
Development, diﬀerentiation, and homeostasis are con-
trolled by cell-cell interactions, cell-extracellular matrix
(ECM) interactions, and soluble cues (hormones, cytokines,
and growth factors) [1, 2]. Cell adhesion to ECM occurs
through interactions between speciﬁc integrin receptors and
ECM counterparts. These interactions cause the transduc-
tion of many diﬀerent signals that regulate cellular functions,
such as gene expression, diﬀerentiation, proliferation, and
motility. Importantly, an appropriate adhesion to ECM
components determines whether a cell is in the correct
location and thus regulates cell survival and cell death.
In 1994, Frisch and Francis noticed that loss of matrix
attachment of epithelial cells resulted in apoptosis [3]. They
referred to this form of programmed cell death that occurs
upon detachment from the appropriate ECM as anoikis
[4–6]. Because anoikis prevents detached epithelial cells
from colonizing elsewhere, thereby inhibiting dysplastic cell
growth or attachment to an inappropriate matrix, anoikis
is a physiologically relevant process for tissue homeostasis
and development. Dysregulation of anoikis, such as anoikis
resistance, is a critical mechanism in tumor metastasis.
Epithelial cancers initially arise as an organ-conﬁned lesion,
but eventually spread to distinct organs through the blood-
stream, generating metastatic lesions that are responsible for
most cancer-related lethality. The tumor cells that acquire
anoikis resistance can survive after detachment from their
primary site and while traveling through the vascular system
untiltheycolonizethedistalorgan[4–7].Inaddition,anoikis
resistance is also important for the peritoneal dissemination
of gastric and ovarian cancer cells [6, 8]. This paper will
focusonthecurrentunderstanding ofcellularandmolecular
mechanisms of anoikis resistance.
2.A dhesio nandC ellS urvi val
For survival and proliferation, normal epithelial cells require
adhesion to speciﬁc ECM components through cell surface
receptors known as integrins. Integrins are heterodimers
consisting of α-a n dβ-subunits. There are at least 24 distinct
integrin heterodimers assembled by the combination of 182 International Journal of Cell Biology
α-subunits and 8 β-subunits. Because speciﬁc integrin het-
erodimers preferentially bind to distinct ECM components,
the repertoire of integrins on the cell surface guides where
the cell adheres or migrates. Integrin expression patterns
vary between normal tissue and tumors [1, 6, 9]. Although
integrins αvβ1, α5β1, and αvβ6 are usually expressed at
low levels, they are highly upregulated in some tumors,
whereas some integrins, such as α2β1, are decreased in
tumor cells. Integrin ligation regulates not only cell adhesion
and migration but also cell survival. Ligated integrins
transduce survival signals, whereas unligated integrins can
promote a proapoptotic cascade, thereby preventing cells
from surviving in an inappropriate environment [2].
Integrins activate multiple signaling pathways that reg-
ulate cell motility and survival through interactions with
cytoplasmic kinases, small G-proteins, and scaﬀolding pro-
teins. Integrin ligation activates FAK, a nonreceptor tyro-
sine kinase, and activated FAK phosphorylates itself and
other cellular proteins. FAK autophosphorylation at Y397
provides a binding site for SH2 domain-containing proteins
such as Src family kinases and the p85 subunit of PI3K,
which is important for integrin-mediated cell growth and
migration [2, 6]. Integrin ligation activates the NF-κBa n d
PI3K/Akt pathways and upregulates prosurvival proteins,
Bcl-2 and FLIP, thereby enhancing cell survival [10]. Cross-
talk between growth factor receptors and integrins activates
Raf, which also promotes cell survival [6]. Although cell
adhesion is critical for cell growth in normal tissues,
adhesion-dependent control of cell growth is dysregulated
in tumor cells, as anchorage-independent growth is promi-
nently implicated in malignant transformation.
Recently, CUB domain-containing protein 1 (CDCP1),
a transmembrane glycoprotein, has been linked to a noble
pathwayofanoikisresistanceindependentofRas-MAPKand
PI3K-Akt pathways in lung cancer and gastric cancer cell
lines [11, 12]. Cell detachment induces CDCP1 phospho-
rylation by Src family kinases (SFKs) including Src, Fyn,
and Yes. Upon SFK-mediated tyrosine phosphorylation of
CDCP1, PKCδ forms a complex with CDCP1 and SFKs, is
phosphorylated by SFKs and activated, leading to anoikis
resistance [12]. Interestingly, CDCP1 phosphorylation by
SFKs further activates SFKs and enhances metastasis in
melanoma, indicating a “feed-forward loop” to maintain
elevated activity of SFKs during tumor progression although
the cause of the initial activation of SFKs is not clear [11, 13].
Resistance to detachment-induced cell death, or anoikis
resistance, is emerging as a hallmark of metastatic malignan-
cies, because it can ensure anchorage-independent growth
and survival during tumor dissemination [4–6]. Numerous
studies have suggested that stimulation of prosurvival signals
and suppression of death signals are involved in anoikis
resistance.
3.ProsurvivalSignalsandApoptotic Signalsin
AnoikisResistance
The role of the death receptor and the mitochondrial
pathway in anoikis and anoikis resistance has been reviewed
recently [5]. The death receptor (extrinsic) pathway is
initiated by ligation of members of the TNF receptor
superfamily, such as Fas and TNF-R1, causing the forma-
tion of the death-inducing signaling complex (DISC) as
described in the Figure 1. Upon DISC formation, caspase-
8 (FLICE) is activated and released into the cytoplasm
where it cleaves caspase-3 and caspase-7. These activated
eﬀector caspases cleave cellular substrates, culminating cell
death. FLIP (FLICE-inhibitory protein) has a higher aﬃnity
for the DISC than caspase-8 and is preferentially recruited
to the DISC, thereby inhibiting caspase-8 recruitment and
activation[5,14,15].Anoikisemploysthisextrinsicpathway,
at least partially. For example, matrix attachment protects
cells from Fas-induced apoptosis, whereas matrix detach-
ment sensitizes cells to Fas-mediated apoptosis. After cell
detachment, FasL and Fas receptor are upregulated but FLIP,
an endogenous antagonist of caspase-8, is downregulated,
which leads to caspase-8 activation in human umbili-
cal vein cells (HUVECs) [16, 17]. In addition, unligated
integrin recruits caspase-8 to the membrane, where it
becomes activated in a death receptor-independent man-
ner, whereas integrin ligation disrupts this integrin-caspase
complex and increases survival [18]. Caspase-8 activation
triggers anoikis but FLIP overexpression, which inhibits
caspase-8 activation and blocks anoikis in keratinocytes
and HUVECs [16, 17]. Malignant cells avoid anoikis by
overexpressing FLIP [5]. Anisomycin can sensitize cells
to anoikis by decreasing FLIP protein levels and inhibits
distal tumor formation in a mouse model of prostate
cancer metastasis [19].
In the mitochondrial (intrinsic) pathway, proteins of
the Bcl-2 family are key players and include anti-apoptotic
proteins, such as Bcl-2, Bcl-xL, and Mcl-1, and proapop-
totic proteins, such as the BH3-only proteins Bid, Bad,
Noxa, Puma, and Bim, as well as Bax, Bak, and Bok
[20]. In response to death signals, monomeric Bax or Bak
translocate from the cytosol to the outer mitochondrial
membrane (OMM) where they form oligomers, causing
mitochondrial permeabilization and release of cytochrome
c and Smac/DIABLO. Released cytochrome c triggers
caspase-9 activation and consequently caspase-3 activation.
Smac/DIABLO impedes the function of inhibitor of apop-
tosis proteins, IAP and XIAP. Bcl-2 exerts its antiapoptotic
function by binding to pro-apoptotic proteins, Bax and
Bad, preventing their oligomerization and thus maintaining
mitochondrial membrane integrity. BH3-only proteins com-
pete with Bcl-2 for binding with apoptotic activators, thus
promoting apoptosis [21].
The mitochondrial (intrinsic) pathway is activated dur-
ing anoikis. Bid translocates to the OMM following loss
of adhesion with identical kinetics with Bax, which is
required for anoikis of mammary epithelial cells [22]. Bim
is sequestered by dynein cytoskeletal complexes when cells
are attached to ECM. Cell detachment induces release of
Bim from these complexes and causes its translocation to the
mitochondria, where it interacts with Bcl-xL, neutralizing
its prosurvival function [23, 24]. Loss of cell adhesion also
causes the accumulation of cytoplasmic Bim via inhibiting
its proteasomal degradation initiated by its phosphorylation
through the ERK and PI3K/Akt pathways. Activated Bim
promotes Bax-Bak oligomerization within the OMM andInternational Journal of Cell Biology 3
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Figure 1: Schematic representation of intrinsic and exrtinsic pathways of anoikis. When cells are detached from ECM, normal cells induce
anoikis through both intrinsic and exrtinsic pathways. Upon cell detachment, FAS and FasL are upregulated and FLIP is downregulated,
leading to activation of Caspase 8, followed by activation of caspase-7 and caspase-3. Loss of cell adhesion also increases and activates
proapoptotic Bcl-2 proteins (Bik, Puma, Bad, Noxa, Bmf, Bid, Bim, Bax, and Bak), which inactivate antiapoptotic Bcl-2 proteins (Bcl-2,
Bcl-xL, Mcl-1), and thus causing mitochondria membrane permeabilization through Bax/Bak oligomerization. Released cytochrome c from
mitochondria activates caspase-9, subsequently caspase-3. Smac/DIABLO is released and inhibits XIAP, an inhibitor of apoptosis, leading
to caspase-3 activation. Activaiton of these pathways leads to anoikis. However, increased FLIP expression in cancer cells inhibits extrinsic
pathway and oncogene expression such as EGFR and hypoxia downregulate Bmf and Bim, resulting in inhibition of mitochondrial pathway
in suspended cells. Accordingly, cancer cells acquire anoikis resistance.
inducesintrinsicapoptosispathwayuponcelldetachment[4,
24]. Bcl-2 modifying factor (BMF) is sequestered to myosin
V motor complexes and, upon loss of cell attachment, is
released. BMF then binds to antiapoptotic Bcl-2 to initiate
anoikis in human intestinal epithelial cells [4, 25, 26]. Both
Bim and BMF are associated with cytoskeletal structures
and counteract the activity of antiapoptotic Bcl-2 when cell
adhesion is disrupted. Therefore, suppression of Bim and
BMF could confer anoikis resistance. In fact, overexpression
of EGFR blocks both Bim expression and anoikis [27]a n d
hypoxia decreases Bim and BMF expression and blocks
anoikis in mammary epithelial cells [28].
4. EMT andAnoikisResistance
During metastasis, epithelial cancer cells are released from
their environment by breaking the basement membrane
barrier. This process is involved in epithelial-mesenchymal
transition (EMT). EMT is the biological process through
which polarized epithelial cells undergo multiple biochem-
ical changes, leading to a mesenchymal phenotype, such as
enhanced migratory capacity, invasiveness, and resistance
to apoptosis [29]. EMT is an essential process during
development and is also induced during tissue repair and
pathological processes, including inﬂammation and high-
grade carcinomas in adults. EMT is characterized by loss of
several epithelial proteins, including E-cadherin, β-catenin,
andγ-catenin.Itisalsoaccompaniedbyincreasedexpression
of mesenchymal proteins, such as N-cadherin, vimentin,
ﬁbronectin, and smooth muscle actin. The signiﬁcance of E-
cadherin loss in metastasis has been shown in a variety of in
vitroand in vivo models [30, 31] and loss of E-cadherin is the
major hallmark of EMT. Loss of E-cadherin may be achieved
through the upregulation of transcriptional repressors of E-
cadherin, including E12/E47, Twist, and members of the Zeb
and Snail protein families. Transforming growth factor-β
(TGF-β), an inducer of EMT, upregulates these transcription
factors, thereby promoting EMT and metastasis [32, 33].
EMT is not only a key event for epithelial-derived cells to
acquire a motile and invasive phenotype but also an essential
process for anoikis resistance [34]. EMT-promoting proteins
are linked to anoikis resistance. Loss of E-cadherin induces
anoikis resistance and promotes metastasis and N-cadherin
expression also induces anoikis resistance [35]. Twist is the
mediator of loss of E-cadherin-induced anoikis resistance
[36, 37]. Conditional knockdown of E-cadherin and p53 in
mammary epithelium induces mammary tumor initiation,
metastasis, and anoikis resistance in the mouse model [37].
Moreover, the loss of E-cadherin induces Twist expression,
indicating a feed-forward loop to maintain EMT [38]. Neu-
rotrophic tyrosine kinase receptor B (TrkB) induces EMT,4 International Journal of Cell Biology
and knockdown of Twist blocks TrkB-induced EMT, anoikis
resistance, and tumor growth. Moreover, Snail was induced
by Twist, and silencing of Snail impairs EMT and anoikis
resistance [39]. Twist is upregulated in several malignancies
and promotes EMT, and Zeb and Snail are often overex-
pressed in metastasizing tumors [36, 40]. Knockdown of
Zeb1 induces E-cadherin expression and inhibits cell growth
in anchorage-independent conditions [41]. Zeb1, acting
downstream of Twist and Snail, is also required for TrkB-
induced EMT, anoikis resistance, and metastasis [42]. The
E-cadherin-interacting protein, ankyrin-G, mediates anoikis
regulatory signals, and binds with neurotrophin receptor-
interactingMAGEhomolog(NRAGE).NRAGErepressesthe
p14ARF gene and suppresses anoikis [43]. Recently, Shin et
al. [44] reported that activation of EKR2 but not EKR1 is
necessary for Ras-induced EMT in MCF-10A cells that are
transformedbyoncogenicRas.ERK2activationresultsinthe
Fra1 upregulation, which in turn triggers the accumulation
of Zeb1/2, thereby inducing EMT and increasing migration,
invasion, and survival. In addition, TGF-β induces EMT
via isoform switching of FGF receptors, causing the cells
to be more sensitive to FGF-2, which activates the MEK-
ERK pathway to regulate complex formation of Zeb1 with
transcription corepressor CtBP1 [45].
DuringtheEMTprocess,E-cadherinexpressionisdown-
regulated whereas N-cadherin expression is up-regulated,
referred to as a “cadherin switch” [46]. E/N-cadherin switch
promotes cancer progression via TGF-β-induced EMT in
extrahepatic cholangiocarcinoma [47]. N-cadherin expres-
s i o na p p e a r st ob em o r ec r i t i c a lf o rt u m o rm a l i g n a n c yt h a n
E-cadherin. N-cadherin promotes cell motility and invasion
via interactions with growth factor receptors such as FGF
receptors and PDGF receptor. N-cadherin also promotes
cell growth and survival by repressing apoptotic signals
and numerous clinical studies have shown that aggressive
human tumors express N-cadherin in situ, indicating a
critical role for cadherin switch in human tumorigenesis
[48]. Accordingly, both EMT and anoikis resistance are key
processes for metastasis and they share common regulators,
such as Twist, Snail, Zeb1, E-cadherin, and N-cadherin
(Figure 2).
5. Growth Factor Receptors and
AnoikisResistance
Unregulatedexpressionofgrowthfactorreceptorsorcompo-
nents of their signaling pathways are associated with tumor
malignancy due to their inhibition of cell death pathways
and activation of cell survival pathways [49]. Abnormal
regulation of growth factor receptors activates prosurvival
signaling pathways, such as the PI3K/Akt, Ras/MAPK, NF-
κB, and Rho-GTPase pathways [1, 49], leading to metastasis
byinhibitinganoikis.Thiscanbeachievedthroughautocrine
signaling of growth factors, including ﬁbroblast growth
factor (FGF), hepatocyte growth factor (HGF), and platelet-
derived growth factor (PDGF). In addition, overexpression
of growth factor receptors, such as EGF receptor, TrkB
receptor, and HGF receptor, can suppress anoikis.
Anoikis
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E-cadherin ↓
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Figure 2: Schematic representation of EMT and anoikis resistance.
EMT-inducing factors, such as TGF-β and FGF activate transcrip-
tional factor, Twist, Snail and Zeb1. Activated these transcriptional
factors repress E-cadherin (encoded CDH1 gene) expression and
induce N-cadherin expression (Cadherin switch). Cadherin switch
induces EMT and anoikis resistance, which are associated with
tumor metastasis.
ErbB family members are tightly linked to tumor pro-
gression and malignancies through the activation of many
diﬀerent signaling pathways for cell proliferation, survival,
and migration [49]. Upon detachment from ECM, EGFR
(ErbB1) is downregulated and Bim is upregulated, which
is a critical mechanism for anoikis. Overexpression of EGF
receptor maintains ERK activation in suspended cells and
blocks anoikis via suppression of Bim expression in MCF-
10A cells, indicating that growth factor receptor expression
uncouples anoikis from integrin regulation [27]. Moreover,
ErbB2 overexpression blocks Bim expression and anoikis, via
upregulation of α5 integrin and activation of Src in ECM-
detached cells [50]. Loss of ECM attachment downregulates
EGF receptor and β1 integrin both at the protein and
mRNA levels. However, ErbB2 overexpression rescues both
EGF receptor and β1 integrin protein via ERK and Sprouty,
which stabilizes EGF receptor in ECM-detached cells [51].
Cell detachment causes ATP deﬁciency due to the decreased
glucosetransportbutthisdeﬁciencycanberescuedbyErbB2
overexpression,whichstabilizesEGFreceptorexpressionand
thus PI3K activation [52]. TGF-α,al i g a n df o rE G Fr e c e p t o r ,
prevents anoikis of intestinal epithelial cells by reversing the
loss of Src activity and Bcl-xL expression induced by cell
detachment [53]. Anchorage-independent Ewing sarcoma
cells suppress anoikis through a pathway involving E-
cadherin cell-cell adhesion, which leads to ErbB4 activation
of the PI3K/Akt pathway [54]. The PI3K/Akt pathway plays
ac r i t i c a lr o l ei nc e l ls u r v i v a la n dP T E N ,o n eo ft h em o s t
frequently mutated tumor suppressors in human cancer,
negatively regulates the PI3K/Akt pathway [55]. PTEN also
plays an important role in the anoikis induction through
negative regulation ofFAK. Overexpressionof PTENinducesInternational Journal of Cell Biology 5
anoikis via suppression of the phosphorylation of FAK and
Akt in human bladder transitional carcinoma cells [56]a n d
in U251 glioma cells [57]. Accordingly, loss of PTEN confers
apoptotic resistance to cell rounding and matrix detachment
in human mammary epithelial cells [58].
Insulin-like growth factor 1 (IGF-1) is a well-established
cell survival factor that triggers Akt activation after loss
of matrix contact [59]. IGF-1 receptor prevents anoikis in
mouse embryo ﬁbroblasts [60] and in the LNCaP human
prostateepithelialcellline[59].DisruptionofIGF-1receptor
signaling decreased the number of circulating tumor cells
in the blood of tumor-bearing mice and enhanced anoikis
of LCC6 cells, a metastatic variant of MDA-MB-435 breast
cancer cells [61]. Many studies have reported that PDGF
receptor is also associated with metastasis of tumor [62–64].
PDGF receptor acts as the upstream tyrosine kinase for Src, a
key contributor for anoikis resistance, in a human lung ade-
nocarcinoma upon cell detachment [65]. The cooperation
of autocrine PDGF-PDGFR signaling with oncogenic Ras
strongly activates PI3K and is required for survival during
EMT [66]. Transforming growth factor-β (TGF-β) and its
receptor also play critical roles in tumor progression and
metastasis. TGF-β1 coordinately and independently activates
FAK and Akt kinase pathways through the early activation of
SMAD3 and p38 MAPK, respectively, to confer an anoikis
resistant phenotype to myoﬁbroblasts [67]. In addition,
in conjunction with EGF, TGF-β1 enhances migration,
invasion, and anchorage-independent growth compared to
that induced by EGF alone through the activation of MAPK
and Akt [68]. Accordingly, the TGF-β inhibitor, LY2109761,
suppresses metastasis of pancreatic cancer by inducing
anoikis [69]. Conditional activation of FGF receptor causes
anchorage-independent growth and EMT in a ribosomal S6
kinase-dependent manner in MCF-10A cells [70]. HGF and
its receptor inhibits anoikis of pancreatic carcinoma cells
through the PI3K pathway and of head and neck squamous
carcinoma cells through activation of ERK and Akt signaling
[71,72].VascularendothelialgrowthfactorA(VEGF-A)and
its main signaling-receptor VEGFR2 (KDR) are expressed in
primary ovarian tumors and autocrine VEGF-A/KDR loop
protects ovarian carcinoma cells from anoikis [73].
6. EnergyMetabolism, Autophagy, ROS,
andAnoikisResistance
Rapidly dividing tumor cells require rapid ATP generation,
increased biosynthesis of biomolecules, and maintenance of
an appropriate redox status to support cell division, despite
the low oxygen (hypoxia) and nutrient levels within the
tumor[74].Tumorcellsreprogramtheirmetabolicpathways
to meet these needs. The best-characterized metabolic phe-
notype in tumor cellsis marked by the Warburg eﬀect,which
is a shift from ATP generation through oxidative phospho-
rylation to ATP generation through glycolysis, even under
normal oxygen concentrations [75]. This aerobic glycolysis
is regulated by PI3K/Akt [76, 77], hypoxia-inducible factor
(HIF) [78–82], p53 [83–85], Myc [77, 86, 87], and AMP-
activated protein kinase (AMPK)-liver kinase B1 (LKB1)
[88–90] pathways. Alternatively, stress conditions, such as
limited nutrients and hypoxia, activate autophagy to buﬀer
metabolic stress during tumor growth [91].
An elegant model for the study of anoikis has been
developed and provides insight into the mechanisms of
detachment-induced apoptosis. Three dimensional culture
of MCF-10A mammary epithelial cells form spheroid
structures, termed acini, in which a layer of polarized
epithelial cells surrounds a hollow lumen, resembling glan-
dular epithelium in vivo. This lumen formation involves
the clearance of central cells by selective anoikis of cells
lacking ECM attachment [91]. When MCF-10A cells are
detached from the ECM, glucose uptake is decreased, energy
production is reduced [52]. Overexpression of ErbB2 has
been linked to anoikis resistance. In line with this report,
overexpression of ErbB2 rescues ATP deﬁciency by restoring
glucose uptake through EGF receptor stabilization and PI3K
activation, which is consistent with the studies that the
PI3K/Akt pathway activates glucose uptake and protects
cancer cells from starvation [52, 92]. Lack of glucose uptake
in the detached cells blocks both glycolysis and the pentose
phosphate pathway (PPP). In addition to macromolecular
building blocks, PPP produces NADPH, a crucial cellular
reducing agent, quenching the reactive oxygen species (ROS)
produced during cell metabolism [74]. Accordingly, in the
detached cells, ROS levels are increased and antioxidant
treatment rescues low ATP levels by permitting fatty acid
oxidation, leading to the ﬁlling of the luminal space in
MCF-10A acini. An increase in oxidative damage blocks the
consumption of fatty acids for energy production, and thus
detached epithelial cells experience severe starvation and
death. However, expression of the ErbB2 oncogene enables
MCF-10A cells to overcome anoikis because there is enough
ATP production with continuous glucose uptake.
Autophagy is a tightly regulated lysosomal self-eating
process that is upregulated during cellular stress, such as
deprivation of nutrients and growth factors. Autophagy
produces nutrients and energy to enhance cell survival
through the breakdown of cytosolic components. Basal
levels of autophagy are required to maintain homeostasis
by removing damaged proteins and organelles. Although
autophagy is essential for cell survival, excessive autophagy
results in programmed cell death. Autophagy is regulated by
autophagy-related genes (ATGs), and the majority of pro-
autophagic events converge on the mammalian target of
rapamycin (mTOR) pathway [93]. Autophagy is known to
suppress tumor formation by limiting chromosomal insta-
bility and promoting cellular senescence [94]. In contrast,
protumorigenic functions for autophagy have been pro-
posed and demonstrated. Autophagy is increased in cancer
cells during many of the conditions directing metastasis,
including hypoxia, metabolic stress, and cell detachment
from ECM [93]. Silencing of autophagy regulators inhibits
detachment-induced autophagy and enhances apoptosis,
indicating that autophagy promotes epithelial cell survival
during anoikis [91]. Recently, it was reported that oncogenic
H-Ras expression induces autophagy upon cell detach-
ment [95]. Interestingly, genetic deletion or RNAi-mediated
knockdown of autophagy regulators decreases cell growth6 International Journal of Cell Biology
in soft agar and reduces glycolysis, indicating that an intact
autophagy pathway is required for adhesion-independent
transformation and facilitates glycolysis through oncogenic
H-Ras [95]. These studies suggest that anoikis resistance
is associated with tolerance to bioenergetic stress due to
oncogene expression.
The balance between oxidation and reduction plays a
critical role in the cellular signaling pathways involved in
cell growth and metastasis. Elevated oxidative stress is more
frequently observed in many solid tumors and carcinoma
cell lines than in normal cells. ROS are now recognized as
key second messengers during growth factor and cytokine
stimulation to elicit prosurvival signals. Upon integrin
engagement, ROS are produced via Rac-1, and elevated
ROS induce prosurvival signaling through Src activation.
Activated Src phosphorylates EGF receptor in a ligand-
independent manner, which activates the ERK and Akt path-
ways,leadingtoBimdegradationandsuppressionofanoikis.
Src activation plays a critical role in anoikis resistance.
Src is transiently activated upon cell detachment, which
delays anoikis in intestinal epithelial cells [96]. In addition,
in metastatic prostate cancer cells, ROS are constitutively
produced due to sustained activation of 5-lopoxigenase (5-
LOX). These ampliﬁed and persistent redox signals activate
Src in the absence of adhesion, thereby sustaining ligand-
independent EGFR activation. This pathway degrades pro-
apoptotic protein Bim, thereby promoting anoikis resistance
[97]. Elevated expression of angiopoietin-like 4 (ANGPTL4)
is widespread in tumors and its role in anoikis resistance has
been recently reported [98]. ANGPTL4 binds to β1a n dβ5
integrins directly, which stimulates NADPH oxidase (NOX)-
dependent production of O
−
2 .Ah i g hr a t i oo fO
−
2 :H 2O2
activates Src, triggering the prosurvival PI3K/Akt and ERK
pathways to confer anoikis resistance.
7. Membrane Microdomainsand
AnoikisResistance
Another way to regulate anoikis is through modulation
of membrane microdomains, including lipid rafts. This
topic was recently reviewed [99]. There are two distinct
types of lipid rafts: planar lipid rafts (noninvaginated
rafts) and invaginated rafts known as caveolae. Caveolae
are characterized by speciﬁc scaﬀolding proteins, called
caveolins. Sphingolipids and cholesterol are the major lipid
components of lipid rafts, and cholesterol is critical for the
intact structure of lipid rafts. Because cell surface receptors,
such as integrins and growth factor receptors, and some
intracellular signaling molecules are enriched in lipid rafts,
lipid rafts are regarded as the sites of assembly and initiation
of signaling pathways [100, 101].
Caveolin-1, a structural protein for caveolae, acts as a
scaﬀolding protein via its binding to signaling molecules
such as EGF receptor, Src family members, MAPK, PKC,
endothelial nitric oxide synthase (eNOS), and G-protein α
subunits through its scaﬀolding domain [101]. This binding
is known to negatively regulate these molecules. Initially,
caveolin-1 was regarded as a tumor suppressor because it
is downregulated in transformed cells and re-expression
of caveolin-1 inhibits colony formation and induces apop-
tosis in transformed cells and breast cancer cells [102].
However, caveolin-1 levels are elevated in prostate cancer
and lung adenocarcinomas, and the elevated caveolin-1
levels are associated with increased metastatic capacity and
poor prognosis [103, 104], indicative of an oncogenic
role for caveolin-1. Several studies have demonstrated that
caveolin-1is associated with anchorage-independent growth.
Caveolin-1 expressioninhibits anoikis byinhibiting p53 acti-
vation and activating IGF receptor-mediated ERK and Akt
signaling pathways upon cell detachment [105]. In human
lung carcinoma H460 cells, caveolin-1 is downregulated
during cell detachment through a mechanism involving
ubiquitin-mediated proteasomal degradation. Interestingly,
nitric oxide (NO) prevents downregulation of caveolin-
1 by ubiquitination and this event suppresses anoikis
[106]. Alternatively, increased levels of hydrogen peroxide in
detachedcellspreventcaveolin-1degradationandstabilizeit,
thereby inhibiting anoikis [107]. Overall, caveolin-1 appears
to have dual functions depending on the cell type: as a
tumor suppressor by inhibiting anchorage-independent cell
growth and as a promoter of tumor metastasis by preventing
anoikis.
Lipid rafts are associated with integrin signaling. Thus,
modulation of lipid rafts is linked to adhesion-dependent
cell survival. Cell detachment triggers internalization of lipid
rafts, and inhibition of lipid raft internalization maintains
Rac1 membrane targeting and downstream eﬀector acti-
vation in suspended cells [108]. This study indicates that
integrins regulate lipid raft localization, thereby controlling
anchorage-dependent cell growth. In line with this notion,
disruption of lipid rafts by cholesterol depletion results in
FAK down-regulation, cell detachment, lipid raft internal-
ization, and anoikis-like cell death in A431 human cervical
cancer cells [109, 110]. Lipid raft disruption induces tyrosine
phosphorylation of caveolin-1 through Src activation, which
could be involved in lipid raft internalization. Caveolin-1 is
tyrosine phosphorylated by Src and EGF-receptor signaling
[99, 111], and this phosphorylation has been shown to
be involved in caveolae internalization [112]. Under lipid
raft disrupting stress, HIF-1α is induced via EGF receptor
activation, which delays anoikis. This is consistent with
the ﬁnding that knockdown of HIF-1α accelerates anoikis
[113]. Aloe-emodin is an anthraquinone derivative that
alterslipidraftsbydecreasingsphingolipidandcholesterolin
thelipidraftfraction.Itinhibitstumorcelladhesionthrough
disruption of the lipid raft-associated integrin signaling
pathways, such as FAK recruitment to β1 integrin [114]
and it sensitizes anoikis in gastric carcinoma cells and lung
cancer H460 cells [115, 116]. Akt activation is important
for cell survival and anoikis resistance [4]. Intact lipid rafts
are critical for PI3K/Akt signaling because they facilitate
Akt recruitment and activation upon phosphatidylinositol-
3,4,5-triphosphate accumulation in the membrane [117].
Lipid rafts disruption by cholesterol depletion results in both
lipid raft internalization and Akt inactivation even in the
presence of EGF stimulation. Cholesterol repletion reverses
these eﬀects [109, 110], indicating that lipid raft localization
in the plasma membrane is important for Akt activation.International Journal of Cell Biology 7
Itispossiblethatmetastatictumorcellspossessamechanism
to regulate lipid raft localization to escape anoikis, which
remains to be investigated further.
8. Conclusion
Normal epithelial cells require adhesion to the appropriate
ECM for survival and proliferation, and loss of this adhesion
induces a type of cell death known as anoikis. Anoikis is
important for normal development and tissue homeostasis
because it prevents detached cells from reattaching to an
inappropriate ECM and growing dysplastically. Anoikis
resistance, or survival in the absence of attachment to ECM,
is a prerequisite for the development of tumor metastases,
the major cause of cancer mortality. Currently, anoikis
dysregulation or resistance has evoked special attention in
the cancer research ﬁelds because circulating tumor cells
in the blood stream are resistant to anoikis, which allows
the cancer cells to disseminate from the primary tumor site
to a distinct lesion. Anoikis is regulated by many diﬀerent
signaling pathways depending on the cell type and expressed
oncogenes. Both the intrinsic and extrinsic death pathways
are employed in anoikis. Expression of oncogenes, such as
ErbB family members, is enable cells to avoid anoikis by
inhibiting apoptotic pathways. In this paper, we included
current data on the mechanisms of anoikis in relation to
alterations of energy metabolism, autophagy, ROS, and lipid
rafts, which are emerging now as a major factor in the
regulation of anoikis and remain to be explored further. A
better understanding of the molecular mechanisms involved
in anoikis resistance would assist in the development of
anticancer drugs to eradicate circulating tumor cells and
prevent tumor metastasis.
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